What the April 2026 FDA peptide reclassification path actually means
A formal process is underway. It is not the same as a final decision.
Update, September 14, 2026: FDA removed 12 peptides from Category 2 on April 22, 2026. Its Pharmacy Compounding Advisory Committee met on July 23–24, 2026. This article was first written in April 2026 and now reflects those events.
TL;DR
- In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
- On April 22, 2026, FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 after their nominations were withdrawn. As of September 14, 2026, none of the 12 is in any FDA 503A category or on the 503A bulks list.
- The Pharmacy Compounding Advisory Committee met on July 23–24, 2026. It voted to recommend six of the seven peptides it reviewed and voted against emideltide (DSIP). As of September 14, 2026, FDA has not made a final decision.
What it is
"FDA peptide reclassification" is shorthand for moving a peptide between FDA's interim categories. Category 1 lists substances FDA is still evaluating. FDA's policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to Category 1 substances, when other conditions are met. Category 2 lists substances FDA says raise significant safety risks. The framework comes from the FDA's bulks list rulemaking under the Drug Quality and Security Act (DQSA), which governs what compounding pharmacies are permitted to mix.
In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. On April 22, 2026, FDA removed 12 peptides from Category 2. It did not move them to Category 1.
How it works
Picture the procedure for adding a peptide to the Section 503A bulk drug substances list as a multi-stop train, not a single stop. The train looks like this:
- HHS or FDA policy announcement. Signals direction. Not legally binding.
- Pharmacy Compounding Advisory Committee (PCAC) review. A federal advisory committee evaluates the science and the compounding context.
- Federal Register proposed rule. The legal proposal goes public for comment.
- Public comment period. Stakeholders submit comments — patients, pharmacists, physicians, manufacturers.
- Final rule in the Federal Register. The legal change takes effect on the date the final rule specifies.
The April 2026 category change did not follow this train. FDA removed the 12 peptides from Category 2 because their nominations were withdrawn. For the bulks list, stop 2 took place on July 23–24, 2026, when the committee reviewed seven peptides. As of September 14, 2026, FDA has not taken a further step.
Who asks about it
People come to this question through three doors: news coverage of Secretary Kennedy's February 2026 remarks and FDA's April 2026 category change, frustration with Category 2 access limits, and physician communication about what may change later in the year.
What the research says
The procedural framework is described in the FDA's compounding Q&A and in the Federal Register process for rulemaking (FDA — Compounding Q&A; Federal Register). The clinical evidence base for the affected peptides is largely preclinical, which was part of what PCAC evaluated in July 2026.
What to know before considering it
Removal from Category 2 did not, by itself, put any of these peptides on the 503A bulks list or in Category 1. Avoid sources that describe these peptides as "legal again" before the Federal Register confirms it. Any clinical use of the affected peptides requires a licensed prescriber's evaluation under the current framework.
The Halftime POV
A policy announcement is a starting gun, not a finish line. We want patients to know what is happening, what is not yet happening, and what to watch for. The honest answer in September 2026 is still "in motion, not finished."
Related reading:
- Secretary Kennedy's February 2026 peptide remarks
- Category 1 vs Category 2 peptides: the access framework
- What the July 2026 PCAC meeting could change
FAQ
Q: What is the April 2026 FDA peptide reclassification? A: It refers to FDA's April 2026 change to its Category 2 list. On April 15, 2026, FDA gave notice that 12 peptides would leave Category 2 because their nominations were withdrawn. FDA removed them on April 22, 2026: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. As of September 14, 2026, none of the 12 is in any FDA 503A category or on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Q: Did the FDA already approve compounding for BPC-157 and TB-500? A: Not as a final FDA action. FDA removed BPC-157 and TB-500 from Category 2 on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, neither is in any FDA 503A category or on the 503A bulks list. FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Q: What is the next milestone to watch? A: The Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026, with peptide compounding eligibility on the agenda. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). PCAC's recommendation feeds into the FDA's decision-making, but PCAC does not itself change the law. As of September 14, 2026, FDA has not made a final decision.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- FDA. Compounding and the FDA: Questions and Answers.
- Federal Register — Daily journal of the United States Government.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is the April 2026 FDA peptide reclassification?
It refers to FDA's April 2026 change to its Category 2 list. On April 15, 2026, FDA gave notice that 12 peptides would leave Category 2 because their nominations were withdrawn. FDA removed them on April 22, 2026: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. As of September 14, 2026, none of the 12 is in any FDA 503A category or on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Did the FDA already approve compounding for BPC-157 and TB-500?
Not as a final FDA action. FDA removed BPC-157 and TB-500 from Category 2 on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, neither is in any FDA 503A category or on the 503A bulks list. FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
What is the next milestone to watch?
The Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026, with peptide compounding eligibility on the agenda. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). PCAC's recommendation feeds into the FDA's decision-making, but PCAC does not itself change the law. As of September 14, 2026, FDA has not made a final decision.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.